degenerative disorders, and ischemic stroke. Its core scientific approach combines induced pluripotent stem cell (iPSC) technology with chemical induction methods to generate functional human cell types at scale. This platform is designed to support the development of therapies that can be produced in a consistent and standardized manner, reducing reliance on traditional genetic modification techniques while enabling controlled cell differentiation.

IRegene develops a pipeline of investigational therapies aimed at neurological and degenerative diseases, with lead programs advancing through clinical stages in multiple regions. Its Parkinson’s disease program and other candidates have progressed into early- and mid-stage clinical trials, reflecting a focus on translating laboratory research into human therapeutic applications. The company builds an integrated research ecosystem that includes AI-assisted compound discovery, virtual screening, cell validation systems, and gene-editing tools. These capabilities are used to identify therapeutic candidates, evaluate biological effects, and design delivery systems such as engineered exosomes for targeted treatment applications.